Publications by authors named "C Laclotte"
Background: Adalimumab may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis who had secondary failure to infliximab.
Aim: To evaluate long-term efficacy and safety of adalimumab in patients with ulcerative colitis who previously responded to infliximab, and then lost response or became intolerant.
Methods: We report our single-centre experience in 13 patients.
The current etiologic model of inflammatory bowel diseases proposes a genetically predisposed host responding to a variety of environmental triggers by exhibiting an abnormal immune response to normal luminal flora. Crohn's disease is common in highly industrialized western countries where helminths are rare and uncommon in less developed areas of the world where most people carry worms. From this observation grew the hygiene hypothesis, which states that our failure to be exposed to previously common infectious agents alters the immune repertoire established in childhood.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effectiveness of adalimumab, a medication, for treating ulcerative colitis in patients who had previously responded to infliximab but then lost their response or became intolerant.
- In a 4-week trial with 10 participants, 40% experienced clinical improvement, with 1 patient achieving remission, while 60% showed no response, leading to colectomy in 33.3% of them.
- The findings suggest that adalimumab may offer some benefit in mild to moderate cases of ulcerative colitis, but further research is necessary through larger, controlled trials to confirm these results.
Background: Adalimumab is effective in inducing remission in patients with active Crohn's disease who had secondary failure to infliximab therapy.
Aim: To evaluate the efficacy and safety of adalimumab maintenance therapy in Crohn's disease patients who previously responded to infliximab and then lost response or became intolerant.
Methods: Twenty-four patients with Crohn's disease were enrolled in a 52-week open-label trial.